Targeted Genetics leaps on CF data

[Guest guest]

  Pharma Marketletter

                 June 6, 2003

HEADLINE: Targeted Genetics leaps on CF data

   Shares of US firm Targeted Genetics leapt 76% to $ 2.10 after the company

revealed Phase II clinical trial data showing that its tgAAVC gene therapy

significantly improved cystic-fibrosis patients' lung capacity after 30 days.

The repeat-dosing gene therapy trial showed a statistically-significant

decease

in a cytokine, a natural infection-fighting agent, associated with

inflammation

after 14 days compared with placebo.

   The company said that the therapy was safe and well-tolerated in a

randomized, double-blind, placebo-controlled clinical trial of 37 patients

with

mild CF, who were monitored for around five months.

   The study's lead investigator, Moss of Stanford University Medical

Center, USA, said that a Phase II " confirmatory " study with triple the number

of

CF patients will be now be conducted and is expected to launch " in the coming

months. "

Becki

YOUR FAVORITE LilGooberGirl

YOUNGLUNG EMAIL SUPPORT LIST

www.topica.com/lists/younglung

Pediatric Interstitial Lung Disease Society

http://groups.yahoo.com/group/InterstitialLung_Kids/